Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis

Ann L Walker, Nicolas Ancellin, Benjamin Beaufils, Marylise Bergeal, Margaret Binnie, David Clapham, Carl P Haslam, Duncan S Holmes, Jonathan P Hutchinson, John Liddle, Andrew McBride, Olivier Mirguet, Christopher G Mowat, Paul Rowland, Nathalie Tiberghien, Lionel Trottet, Iain Uings, Scott P Webster, Xiaozhong Zheng, Damian J Mole

Research output: Contribution to journalArticlepeer-review

Abstract

Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington's disease. However, the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible with the intravenous (iv) dosing route required in AP. We have identified and optimized a novel series of high affinity KMO inhibitors with favorable physicochemical properties. The leading example is exquisitely selective, has low clearance in two species, prevents lung and kidney damage in a rat model of acute pancreatitis, and is progressing into preclinical development.

Original languageEnglish
JournalJournal of Medicinal Chemistry
Early online date28 Mar 2017
DOIs
Publication statusPublished - 27 Apr 2017

Keywords

  • Journal Article

Fingerprint

Dive into the research topics of 'Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis'. Together they form a unique fingerprint.

Cite this